A study on relationship of dosage of Amikacin drug with levels in blood.
Not Applicable
- Conditions
- Health Condition 1: A415- Sepsis due to other Gram-negativeorganisms
- Registration Number
- CTRI/2021/08/035823
- Lead Sponsor
- Manipal Center for infectious Diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients diagnosed with sepsis: Infection site suspected, microbiological sampling done, and prescribed with Amikacin as part of therapeutic management.
Patients whose age is > 18 and < 60
Exclusion Criteria
Pregnant or lactating women
Patients who are not willing to give informed consent
Blood transfusion >4 units per week
Patients on dialysis
Patients with chronic kidney disease
Inability to get consent of the patient or next of kin
Second admission to ICU or previous enrolment in study (within same hospital admission)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drug concentrations in blood and pharmacokinetic parameters like clearance, volume of distribution, half-life will be estimated. These parameters will be used for developing dosage protocol.Timepoint: First 8 months - Patient recruitment. <br/ ><br>Next 4 months - Analysis
- Secondary Outcome Measures
Name Time Method pharmacokinetic parameters like clearance, volume of distribution and half life of Amikacin.Timepoint: First 8 months - Patient recruitment. <br/ ><br>Next 4 months - Analysis